Abivax S.A. ABVX 深 沪
等待开盘 10-28 09:30:00 美东时间
94.84
+4.080
+4.50%
华盛通- 最 高94.94
- 今 开91.49
- 成交量 124.27万股
- 最 低 90.85
- 昨 收 90.76
- 总市值 69.78亿
- 52周最高 98.64
- 市盈率 静 --
- 换手率 1.69%
- 52周最低 4.77
- 委 比 66.33%
- 总股本 7357.47万
- 历史最高 98.64
- 量 比 1.88
- 振 幅 4.51%
- 历史最低 4.77
- 每 手 1
- 风险率 32.85%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | NTSK、STUB、WBI获多个机构首予评级；高盛上调雅诗兰黛(EL)评级至"买入"，目标价从76美元升至115美元
今日重点评级关注：花旗：维持Arcus Biosciences"买入"评级，目标价从47美元升至54美元；HC Wainwright & Co.：上调Karyopharm Therapeutics评级至"买入"，目标价15美元
10-14 09:56
Barclays Initiates Coverage On Abivax with Overweight Rating, Announces Price Target of $142
Barclays analyst Etzer Darout initiates coverage on Abivax (NASDAQ:ABVX) with a Overweight rating and announces Price Target of $142.
10-13 19:58
2025年上海市车载吸尘器产品质量监督抽查结果公布
中国质量新闻网讯 据上海市市场监督管理局网站消息，近期，上海市市场监督管理局对本市生产、销售的车载吸尘器产品质量进行了监督抽查。本次抽查了30批次产品。经检验...
10-13 16:52
美股大行评级 | 伯恩斯坦上调阿里巴巴目标价升至200美元；麦格理上调百度评级至"跑赢大市"，目标价升至176美元
今日重点评级关注：摩根大通：维持National Energy Services"超配"评级，目标价从10美元升至19美元；Piper Sandler：维持LENZ Therapeutics"超配"评级，目标价从51美元升至67美元
10-13 11:26
美股大行评级 | 最高300美元，AMD获多家大行上调目标价！
今日重点评级关注：Maxim Group：维持Gain Therapeutics"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Icecure Medical"买入"评级，目标价从2美元升至2.5美元
10-08 09:14
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. ...
10-07 01:35
Why Is Abivax Stock Trading Higher On Monday?
Abivax said Phase 3 trials showed obefazimod improved clinical outcomes in ulcerative colitis, meeting key endpoints with no new safety concerns.
10-06 23:05
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies
Abivax announced positive results from the Phase 3 ABTECT trials for obefazimod in treating moderate-to-severe ulcerative colitis. The 50mg dose showed significant clinical improvements across all endpoints, including for patients with prior inadequate response to advanced therapies, such as JAK inhibitors. Both 25mg and 50mg doses demonstrated similar efficacy for those without prior therapy failure. Obefazimod was well-tolerated with no new saf...
10-06 08:00
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
Abivax announced positive results from its Phase 3 ABTECT trials, showing that the 50 mg once-daily dose of obefazimod achieved a pooled 16.4% placebo-adjusted clinical remission rate at Week 8, meeting primary and secondary endpoints in both trials. The trials enrolled refractory patients, 47% of whom had inadequate responses to previous therapies, including 21% who failed JAK inhibitor treatment. Obefazimod was well-tolerated with no new safety...
10-05 15:00
Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting
Abivax announces the acceptance of an additional late-breaking abstract for obefazimod, its lead drug candidate, to be presented at the 2025 United European Gastroenterology (UEG) Meeting in Berlin. The abstract highlights the efficacy and safety of obefazimod in treating moderately to severely active ulcerative colitis, showcasing statistically significant and clinically meaningful results from the ABTECT-1 and ABTECT-2 Phase 3 trials. Key findi...
09-29 20:05
